

Nuzyra (omadacycline) tablet
Effective 10/01/2026

Plan	☐ MassHealth UPPL ☒ Commercial/Exchange		Program Type	☒ Prior Authorization
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit			☒ Quantity Limit ☐ Step Therapy
Specialty Limitations	N/A			
Contact Information	Medical Benefit Pharmacy Benefit		Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A			

Overview

Nuzyra is a tetracycline class antibacterial indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSSI). Nuzyra should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all of the following criteria are met:

1. Member meets ONE of the following:
 - a. Member was started on Nuzyra in the inpatient setting and is continuing treatment
 - b. ALL of the following:
 - i. Member is 18 years of age or older
 - ii. Diagnosis of ONE of the following:
 - Proven or strongly suspected community acquired bacterial pneumonia (CABP) infection caused by susceptible bacteria (See Appendix A)
 - Proven or strongly suspected acute bacterial skin and skin structure (ABSSSI) infection caused by susceptible bacteria (See Appendix B)
 - iii. Inadequate response, intolerance, or contraindication to a first-line antibiotic indicated for the requested diagnosis (See Appendix C)

Appendix A: Susceptible Microorganisms for Community-Acquired Bacterial Pneumonia (CABP)

- *Streptococcus pneumoniae*
- *Staphylococcus aureus* (methicillin-susceptible isolates)
- *Haemophilus influenzae*
- *H. parainfluenzae*
- *Klebsiella pneumoniae*

- *Legionella pneumophila*
- *Mycoplasma pneumoniae*
- *Chlamydophila pneumoniae*

Appendix B: Susceptible Microorganisms for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

- *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates)
- *Staphylococcus lugdunensis*
- *Streptococcus pyogenes*
- *Streptococcus anginosus* grp. (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*)
- *Enterococcus faecalis*
- *Enterobacter cloacae*
- *Klebsiella pneumoniae*

Appendix C: Examples of First-Line Antibiotics

- Amoxicillin
- Amoxicillin/clavulanate
- Ampicillin/sulbactam
- Azithromycin
- Cefotaxime
- Cefpodoxime
- Ceftriaxone
- Cefuroxime
- Clarithromycin
- Clindamycin
- Doxycycline
- Levofloxacin
- Linezolid
- Minocycline
- Moxifloxacin
- Sulfamethoxazole-trimethoprim
- Vancomycin

Limitations

1. Authorizations will be granted for 14 days.
2. The following quantity limits apply

Drug Name and Dosage	Quantity Limit
Nuzyra 150 mg tablet	30 tablets per 14 days

References

1. Nuzyra (omadacycline) [prescribing information]. Boston, MA: Paratek Pharmaceuticals Inc; May 2026
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.



3. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019; 200:e45.
4. Malcolm C, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. *Arch Intern Med* 2003; 163:797.
5. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011; 52:e18.
6. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis* 2014; 59:147.

Review History

11/20/19 – Reviewed at P&T

11/18/2020 – Reviewed at P&T

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

7/15/2026 – Updated and Reviewed at July P&T. Reformatted criteria and updated appropriate first line treatments per current recommendations under Appendix C. Updated references. Effective 10/01/2026.

